CBIO
$4.74
Catalyst Bio
($.14)
(2.87%)
CBIO
Earnings Whisper ®
N/A
3rd Quarter September 2021
Consensus:  ($0.66)
Revenue:  $1.00 Mil
Thursday
Nov 4
8:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CBIO reports earnings?
Beat
Meet
Miss

Where is CBIO's stock price going from here?
Up
Flat
Down
Stock chart of CBIO
Analysts
Summary of analysts' recommendations for CBIO
Score
Grade
Pivots
Resistance
$5.10
$5.03
$4.88

$4.81

Support
$4.66
$4.59
$4.44
Tweet
Growth
Description
Catalyst Biosciences, Inc. is a biopharmaceutical company which focused on creating and developing medicines to address serious medical conditions. The Company's hemostasis product candidates include CB 813d/PF-0520602, CB 2679d/ISU 304 and FXa. Anti-Complement Product consists of CB 2782 and Ophthalmic which are in clinical different trail. Catalyst Biosciences, Inc., formerly known as Targacept, Inc., is based in South San Francisco, Calif.